Researchers evaluated links between lifestyle and dietary index scores and risk of death in a prospective, multiethnic cohort of men diagnosed with non-metastatic prostate cancer.

A listeria outbreak tied to frozen shakes served in health care facilities has sickened at least 38 people and killed 12, the FDA says.

The US Food and Drug Administration has accepted for priority review the supplemental biologics license application for pembrolizumab (Keytruda) to treat patients with resectable, locally advanced ...

Researchers are projecting that, worldwide, new cases of female breast cancer will increase 38% by 2050, and female breast cancer deaths will increase 68%. These projections and other data were ...

Lea County, New Mexico, is now reporting an outbreak of measles, according to the New Mexico Department of Health.

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

It’s really important to continue to focus on ensuring that those who devote their lives to protecting the public and communities continue to receive coverage through the special claims unit,” said ...

As legal battles over the federal funding freeze and indirect cost payments from NIH play out in court, cancer research is being disrupted.

PE-related deaths among patients with cancer increased 44.3% between 2011 and 2020, rising by about 2.9% each year during the study period ( P <.001). On average, the age-adjusted mortality rate (AAMR ...

GEMSTONE-303 is the first trial demonstrating a statistically significant survival benefit for addition of an anti-PD-L1 antibody to standard chemotherapy for advanced gastric and gastroesophageal ...

Further assessment is needed to understand if these treatment recommendations were eventually adopted and if adoption leads to better outcomes,” researchers wrote.

The FDA has granted priority review to the new drug application for zongertinib to treat adults with unresectable or metastatic, HER2-mutant NSCLC who have received prior systemic therapy.